Evaluating the Diagnostic Utility of Serum SEMA7A, SERPINA3, and ITIH4 in Neurosyphilis Using Enzyme-Linked Immunosorbent Assay
This cross-sectional study evaluated serum levels of SEMA7A, SERPINA3, and ITIH4 in 72 participants and found that while SEMA7A and SERPINA3 lacked diagnostic utility, ITIH4 demonstrated modest potential as a serum biomarker for distinguishing neurosyphilis from non-neurosyphilis cases.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Syphilis is an ancient infection caused by a spiral-shaped bacterium that can travel through the bloodstream and settle deep within the body. While the disease is often treatable, it becomes far more dangerous when the bacteria cross into the brain and spinal cord, a condition known as neurosyphilis. This invasion can cause a wide range of problems, from confusion and personality changes to blindness, hearing loss, and stroke-like symptoms. Diagnosing this specific form of the disease is notoriously difficult because the bacteria hide in the nervous system, often without causing obvious signs in the blood. Currently, doctors rely on a procedure called a lumbar puncture, where a needle is inserted into the lower back to collect fluid from around the spinal cord. This fluid, called cerebrospinal fluid, is then tested for signs of infection. While this method is the gold standard, it is invasive, uncomfortable for the patient, and not always feasible. Because of these challenges, medical researchers have been searching for a simpler way to diagnose the condition using a standard blood test, hoping to find specific proteins in the blood that act as warning signals for the infection.
A team of researchers set out to test three specific proteins that had previously shown promise when found in the spinal fluid. These proteins, known as ITIH4, SERPINA3, and SEMA7A, had been identified in earlier studies as being present in unusual amounts in the brains of people with neurosyphilis. The scientists wanted to know if these same proteins could be detected in the blood serum of patients and if their levels could reliably tell the difference between someone who has the brain infection and someone who does not. To find the answer, they gathered a group of seventy-two people who were being evaluated for possible neurosyphilis at a hospital in China. The researchers carefully sorted these individuals into three distinct categories based on their medical records and test results: those confirmed to have neurosyphilis, those suspected of having it but lacking a definitive diagnosis, and those who had syphilis but no evidence of it affecting the brain. They also divided these groups further to see if the presence of symptoms like headaches or vision changes made a difference in the protein levels.
Using a standard laboratory technique that measures the amount of a specific substance in a liquid, the team analyzed blood samples from all seventy-two participants. They looked for the three target proteins to see if their concentrations changed depending on the patient's diagnosis. The results revealed a clear pattern for one of the proteins, ITIH4. The levels of this protein in the blood were not the same across the three groups. The highest levels were found in the group with no brain infection, and the levels dropped as the likelihood of neurosyphilis increased, reaching their lowest point in the group with confirmed neurosyphilis. While this trend was noticeable, the difference between the groups was not strong enough to be considered a definitive diagnostic tool on its own. When the researchers used statistical methods to see how well ITIH4 could separate patients with the disease from those without, it showed a modest ability to do so, but it was far from perfect.
The other two proteins, SERPINA3 and SEMA7A, told a different story. The researchers found no meaningful difference in the levels of these proteins in the blood, regardless of whether the patient had neurosyphilis, suspected neurosyphilis, or no brain infection at all. The amounts of these proteins in the blood appeared to be random, offering no help in distinguishing between the different groups. Furthermore, the study found that the presence or absence of neurological symptoms, such as dizziness or numbness, did not change the levels of any of these proteins in the blood. This suggests that even if a patient is suffering from severe symptoms, their blood levels of these specific markers do not reflect the severity of their condition.
The findings suggest that while these proteins are indeed involved in the disease process within the brain, they do not travel easily or consistently into the bloodstream in a way that makes them useful for a simple blood test. The researchers propose that the barrier between the brain and the blood, which protects the central nervous system, likely prevents these proteins from leaking out in large enough quantities to be detected reliably. This explains why they were useful in spinal fluid tests but failed in blood tests. The study concludes that while the protein ITIH4 shows a slight connection to the disease, none of the three markers studied are ready to replace the current, more invasive methods of diagnosis. For now, the spinal fluid test remains the most reliable way to confirm neurosyphilis, and these blood proteins cannot yet serve as a standalone solution for doctors.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.